Abbott India Ltd

NSE: ABBOTINDIA BSE: 500488Pharma

Abbott India Ltd is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India.[1] It was established in 1944.[2]

₹27,675

52W: ₹25150 — ₹37000

PE 37.9 · Book ₹2247 · +1132% vs book

Market Cap₹58,809 Cr

Stock P/E37.9Price to Earnings

ROCE44.9%Return on Capital

ROE34.5%Return on Equity

Div. Yield1.67%Face Value ₹10

Strengths

+Company is almost debt free.
+Company has a good return on equity (ROE) track record: 3 Years ROE 35.0%
+Company has been maintaining a healthy dividend payout of 69.6%

Weaknesses

−Stock is trading at 12.4 times its book value
−The company has delivered a poor sales growth of 9.96% over past five years.

Shareholding Pattern

Promoters74.99%

FIIs0.27%

DIIs8.93%

Public15.81%

Category	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	74.99%	74.99%	74.99%	74.99%	74.99%	74.99%	74.99%	74.99%
FIIs	0.18%	0.17%▼0.0	0.17%	0.16%▼0.0	0.16%	0.16%	0.19%▲0.0	0.27%▲0.1
DIIs	8.81%	9%▲0.2	9.01%▲0.0	8.91%▼0.1	9.18%▲0.3	9.11%▼0.1	9%▼0.1	8.93%▼0.1
Public	16.01%	15.86%▼0.2	15.85%▼0.0	15.94%▲0.1	15.67%▼0.3	15.74%▲0.1	15.83%▲0.1	15.81%▼0.0

Financial Statements

Metric	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	1,437	1,439	1,558	1,633	1,614	1,605	1,738	1,757	1,724	1,710
Expenses	1,049	1,109	1,167	1,194	1,178	1,176	1,293	1,255	1,261	1,229
Operating Profit	388	330	391	439	436	429	446	502	463	481
OPM %	27%	23%	25%	27%	27%	27%	26%	29%	27%	28%
Net Profit	311	287	328	359	361	367	366	415	376	395
EPS ₹	146.35	135.09	154.36	168.76	169.78	172.73	172.18	195.43	176.93	185.86

AI Insights

Revenue Trend

Mar 2026 revenue at ₹6,929Cr, up 8.1% YoY. OPM at 27%.

Debt Position

Borrowings at ₹172Cr. Debt-to-equity ratio: 0.04x. Healthy balance sheet.

Capex Cycle

CWIP at ₹6Cr (2% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 8.93% (+0.16pp change). FIIs: 0.27% (+0.08pp change). Promoters hold 74.99%.

Margin & Efficiency

ROCE improving from 40% (Mar 2015) to 45% (Mar 2026). Working capital days: 2.

Valuation

PE 37.9x with 44.9% ROCE. Price is 1132% above book value of ₹2,247. Dividend yield: 1.67%.